Indeed, an increased mutational landscape correlates with cancer progression, as supported by three major facts: (a) the majority of solid tumours and leukaemia consistently exhibit genetic instability, as revealed by both cytogenetic and sequencing data analyses [2]; (b) the high risk of cancer incurred by patients bearing inactivating germline mutations in genes encoding DNA damage response (DDR) proteins, which maintain genome stability [3]; and, inversely, (c) the frequent presence of inactivating mutations in DDR protein-encoding genes in sporadic tumours [4]. The gene discussed is DDR1; the disease is cancer.